SUNNYVALE, California, June 16, 2016 /PRNewswire/ --
Largest Ever Accuray Deal Will Provide More Cancer Patients in the United Kingdom (UK) Access to Advanced, Precise Radiation Treatments
Accuray Incorporated (NASDAQ: ARAY) has a signed deal with NHS Supply Chain for seven TomoTherapy® Systems in a new partnership designed to provide clinicians and their patients with additional access to advanced radiation therapy. This deal was entered into backlog during Accuray's fourth fiscal quarter. This deal with NHS Supply Chain further increases the reach and accessibility of the TomoTherapy System to a wider number of NHS hospitals who wish to make this technology available for the full range of cancer patients.
"This is the largest commitment from a single customer in Accuray history and is the result of our strategic account selling, focus on multi-system orders and customer satisfaction. It continues the validation we are seeing from our customers around the world that the TomoTherapy System is a workhorse system that can handle both routine and complex cancer cases. It underscores customer confidence in the TomoTherapy System as a mainstream radiation therapy device which can be relied upon to provide precise treatment," said Josh Levine, President and Chief Executive Officer at Accuray. "We are committed to continuing to work with UK NHS clinicians and NHS Supply Chain to help ensure cancer patients are able to benefit from the advanced and innovative approaches to treatment the TomoTherapy System uniquely provides."
"NHS Supply Chain is committed to offering high-quality, cost effective radiotherapy treatment systems to the NHS and improving patients' access to new and effective treatment. We believe our latest deal with Accuray will help us achieve these objectives as well as enable us to further support the delivery of the national cancer strategy," said Andy Brown, Managing Director of Capital Solutions at NHS Supply Chain.
For more information on the TomoTherapy System, visit
NHS Supply Chain provides patient-focused healthcare products and supply chain services to the UK's National Health Service. Accuray was awarded onto the latest NHS Supply Chain Imaging, Radiotherapy, Endoscopy and Ancillary Devices Framework Agreement in January 2016, enabling the company to sell its products to NHS hospitals.
The Framework Agreement provides an Official Journal of the European Union (OJEU) compliant, cost effective route to purchase for NHS trusts to use to purchase equipment, including the TomoTherapy System.
Important Safety Information
For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit http://www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, the growth of radiotherapy and access to Accuray's products in the UK and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015, February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.